Immunic, Inc.
NASDAQ:IMUXBiotechnology
-$0.04 today
- Market cap
- $100.83M
- Beta
- 1.39
- P/E (TTM)
- -4.1
- EPS (TTM)
- -$3.46
Volume 0.39M
Average 0.27M
Returns on capital
Immunic, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
1456.2%
avg -22.8%
ROIC
1693.4%
avg 1.5%
ROA
-404.0%
avg -140.7%
Analysis
ROIC is currently the strongest return metric at 1693.4% versus its period average of 1.5%. 2 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Erik Lundgren | Chief Executive Officer & Director | USD 1.13M | 48 | 0 | <0.01% |
Michael A. Panzara | Chief Medical Officer | USD 809.83K | 59 | 0 | <0.01% |
Jason Tardio | Chief Operating Officer & President | USD 751.7K | 49 | 253.00K | 2.56% |
Glenn Whaley | Chief Financial Officer | USD 682.25K | 58 | 120.00K | 1.22% |
Hella Kohlhof | Co-Founder & Chief Scientific Officer | — | 53 | — | — |
Chitrang Davé | Chief Data & Digital Officer | — | — | — | — |
Patrick Walsh | Chief Business Officer | — | 43 | — | — |
Jaa Roberson | Chief People Officer | — | — | — | — |
Jessica Breu | Vice President of Investor Relations & Communications | — | — | — | — |
Inderpal Singh | General Counsel | — | 60 | — | — |
Werner Gladdines | Chief Development Officer | — | 47 | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jun 29, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
No open-market purchases or sales in the last 12 months.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A4 analysts |
| Net Income | N/A | N/A | N/A | N/A4 analysts |
| EBIT | N/A | N/A | N/A | N/A4 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Immunic, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about IMUX's management, answered from reported figures.
Who manages IMUX?
Immunic, Inc. (IMUX) lists 11 active executives. The top listed executive is Hella Kohlhof, Co-Founder & Chief Scientific Officer.
Are IMUX insiders buying or selling?
Recent insider activity shows net buying of $41.01M.
Continue the stock analysis
Jump to another research area for this company.